

Human Genetics in Atherosclerosis: From Targets to Drugs

A Scientific Conference, Co-hosted by Amgen and Stanford Medicine

Monday, August 21, 2017

8:00 a.m. – 5:00 p.m.

McCaw Hall at the Frances C. Arrillaga Alumni Center, Stanford University

Time	Activity/Topic	Details/Speaker
------	----------------	-----------------

8:00 a.m.	Registration Opens	Light breakfast provided (coffee, pastries)
8:30 a.m.	Welcome	Aarif Khakoo, M.D. Vice President, Cardiometabolic Disorders, Amgen Joseph C. Wu, M.D., Ph.D. Director, Stanford University Cardiovascular Institute

Session 1: The Role of Human Genetics in Target Discovery

Session Chair: Vicki Parikh, M.D., Division of Cardiovascular Medicine, Stanford University

8:45 a.m.	Keynote Address: Genetics of Common Diseases	Kári Stefánsson, M.D., Dr. Med. Vice President, deCODE Genetics
9:30 a.m.	Genetic Mechanisms of Coronary Disease: What Can We Learn From Genome-Wide Studies	Tom Quertermous, M.D., Ph.D. Professor of Cardiovascular Medicine, Stanford
10:00 a.m.	Break for Partial Solar Eclipse Refreshments	Limited number of protective eyewear will be provided
10:25 a.m.	Mendelian Randomization to Predict Causality of Cardiovascular Drug Targets Break	Erik Ingelsson, M.D., Ph.D. Professor of Cardiovascular Medicine, Stanford
10:50 a.m.	The Role of Efferocytosis in the Heritable Component of Atherosclerosis	Nick Leeper, M.D., Associate Professor of Vascular Surgery and Cardiovascular Medicine, Stanford
11:15 a.m.	TTC39B: a GWAS Hit for HDL With Multiple Metabolic Phenotypes in Mice and Therapeutic Potential	Alan Tall, M.B.B.S. Professor of Medicine, Columbia University
11:45 a.m.	Panel Discussion	Participants include speakers above and Helina Kassahun, M.D., Clinical Research Medical Director, Cardiovascular TA, Amgen
12:15 p.m.	Lunch	

Session 2: Translating Human Genetics to Therapies

Session Chair: Fatima Rodriguez, M.D., Division of Cardiovascular Medicine, Stanford University

1.15 p.m.	ANGPTL4: Lessons Learned While Developing GWAS-Based Therapeutics	Brandon Ason, Ph.D. Sr. Scientist, Cardiometabolic Disorders, Amgen
1:45 p.m.	Familial Hypercholesterolemia (FH): The Epitome of Personalized Medicine	Josh Knowles, M.D., Ph.D. Assistant Professor of Cardiovascular Medicine, Stanford

2:15 p.m.	PCSK9 Synthesis Inhibition via RNA Interference: Reducing the Burden of LDL-C Management	Clive Meanwell, M.B., Ch.B., M.D. C.E.O., The Medicines Company
2:45 p.m.	PCSK9 Inhibition and the Genetics of Familial Hypercholesterolemia	Scott M. Wasserman, M.D. Vice President, Cardiovascular TA, Amgen
3:15 p.m.	Break	Refreshments
3:30 p.m.	Panel Discussion	Participants include speakers above and Kenneth Mahaffey, M.D., Vice Chair of Medicine for Clinical Research in the Department of Medicine, Stanford University
4:00 p.m.	Closing Remarks	Simon Jackson, Ph.D. Scientific Director, Cardiometabolic Disorders, Amgen Josh Knowles, M.D., Ph.D. Assistant Professor of Cardiovascular Medicine, Stanford
4:15 p.m.	Networking until 5:00 p.m.	Cocktails and Hors d'oeuvres